Aktis Oncology Q1 EPS Estimate Increased by HC Wainwright

Aktis Oncology (NASDAQ:AKTS) – Analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Aktis Oncology in a report issued on Tuesday, March 31st. HC Wainwright analyst R. Burns now expects that the technology company will post earnings of ($0.36) per share for the quarter, up from their previous estimate of ($0.64). HC Wainwright has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.72) EPS and FY2027 earnings at ($2.35) EPS.

A number of other equities analysts also recently commented on AKTS. Leerink Partners assumed coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price objective for the company. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. TD Cowen initiated coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating on the stock. JPMorgan Chase & Co. started coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 target price for the company. Finally, Bank of America assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating and a $34.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $32.00.

Aktis Oncology Stock Performance

AKTS opened at $17.07 on Thursday. The business’s fifty day simple moving average is $19.13. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $29.16.

Insider Activity at Aktis Oncology

In related news, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of Aktis Oncology stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the acquisition, the insider directly owned 5,671,825 shares of the company’s stock, valued at approximately $102,092,850. The trade was a 17.26% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Helen Susan Kim purchased 835,000 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the acquisition, the director owned 5,671,825 shares in the company, valued at approximately $102,092,850. This trade represents a 17.26% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 6,117,776 shares of company stock valued at $110,119,968. 3.30% of the stock is owned by company insiders.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.